Garrett focuses his practice on private equity transactional, portfolio company and general corporate matters. He represents clients across a broad range of industries including private equity funds, technology, health care and consumer goods.
Prior to joining Mintz, Garrett served as a legal intern with a biopharmaceutical company focused on developing cancer treatments. He also served as a legal intern with a pharmaceutical company developing medicine to control the expression of genes. As a business analyst, Garrett worked in supply chain operations with a California-based global information technology company, with a Canadian multinational financial services company, and as a document control officer in the corporate financing division of a Canadian multinational bank.
Experience
- Represented Liberty Power, an independent retail electricity supplier, in its negotiation of a multi-year supply agreement with Boston Energy Trading and Marketing LLC, restructuring of its existing capital structure, and entry into new financing arrangements.
- Represented a national distributed solar developer in its acquisitions of solar energy Project Companies in New York, Massachusetts, New Hampshire, Maryland, Pennsylvania and Texas.
- Represented cloud computing company Rocket Innovations, Inc. in the sale of Rocketbook, the leading smart reusable notebook brand in the United States, to BIC, a global manufacturing company of disposable consumer products such as stationery, lighters, and shavers.
- Represented Capstone Partners, an investment banking and advisory firm serving middle market companies, in its sale to Huntington Bancshares Incorporated (Nasdaq: HBAN).
- Represented Albireo Pharma, a biotechnology company focused on developing treatments for rare disease in its sale to French biotechnology firm Ipsen SA.
- Represented Med-Pharmex, a manufacturer of generic veterinary drugs and portfolio company of private equity firm DW Healthcare Partners, in its sale to Dechra Pharmaceuticals, a British-owned developers and manufacturer of veterinary products.
- Represented XL Fleet Corp., a developer and manufacturer of vehicle electrification solutions, in its de-SPAC merger with Pivotal Investment Corporation II, a special purpose acquisition company.
viewpoints
Restrictive Covenants in Private Equity Transactions
May 14, 2025 | Alert | By Garrett Galvin, David G. Conway, Katya Daniel, Benjamin Ferrucci, Tom J. Pagliarini
Restrictive covenants are unquestionably a significant deal consideration in M&A transactions. In the private equity context, a buyer is focused on restrictive covenants to protect its investment by binding the sellers and other recipients of material deal proceeds to obligations and restrictions for a certain period of time following the transaction. Restrictive covenants serve several purposes and are highly beneficial for a buyer; accordingly, absent any legal limitations and assuming sufficient consideration, a buyer is incentivized to impose restrictive covenants on as many selling parties as possible. However, and not surprisingly, sellers heavily negotiate their post-transaction restrictive covenant obligations to keep their business options as open as possible on a go-forward basis. The conflicting interests of buyers and sellers when it comes to restrictive covenants result in carefully negotiated covenants spread out over multiple transaction documents and employment agreements. This article discusses the common restrictive covenants used in private equity transactions, the importance of such covenants in the key transaction documents, and related enforcement considerations.
Energy & Sustainability Legal Feature — Recently Announced Clean Hydrogen Hub Program Funding
October 13, 2022 | Article | By Garrett Galvin, Alana D. Agron
Read about the Biden-Harris administration’s announcement of $7 billion in funding to create regional clean hydrogen hubs (“H2Hubs”)
Massachusetts Takes a Step Closer to Its 2050 Decarbonization Goal: The Commission on Clean Heat Launch
January 31, 2022 | Blog | By Garrett Galvin
The Beauty and the Terror of Agile Software Development
March 24, 2021 | Advisory | By Alex Civetta, Garrett Galvin
DC Circuit Vacates Trump Administration’s Affordable Clean Energy Rule
February 3, 2021 | Blog | By Garrett Galvin
USCIT Ruling Permits Implementation of Trump Administration’s Bifacial Solar Tariffs
November 30, 2020 | Blog | By Garrett Galvin
FERC Order Removes Barriers for Distributed Energy Resource Aggregations in Wholesale Markets
September 30, 2020 | Blog | By Garrett Galvin
SEC Adopts Amendments to Disclosures of Business (Item 101), Legal Proceedings (Item 103), and Risk Factors (Item 105) Under Regulation S-K
September 14, 2020 | Advisory | By Daniel T. Kajunski, Garrett Galvin
Petition Seeks Federal Overturn of Net Metering, Calls into Question Federal vs. State Authority Over Solar Sales
July 8, 2020 | Blog | By Garrett Galvin
News & Press
Mintz Advises SightLine on its Acquisition of Athena AI
March 12, 2025
Mintz advised SightLine Applications, a leading developer of sensor processing software for autonomous and uncrewed systems, backed by Artemis, on its acquisition of Athena AI, an Australia-based specialist in AI-enabled computer vision and decision support for defense applications.
Mintz Advises Searchlight Cyber on Acquisition of Assetnote
February 11, 2025
Mintz advised Searchlight Cyber, a portfolio company of Charlesbank Capital Partners, on the acquisition of Assetnote, an Australian-based Attack Surface Management (ASM) platform provider.
Mintz Advises Artemis on Acquisition of Richland Glass Company
January 16, 2025
Mintz advised Artemis, a Boston-based private equity firm focused on partnering with differentiated industrial tech companies, on the acquisition of Richland Glass Company, LLC, an Advanced Materials manufacturer of specialty glass containment products and solutions.
Mintz Advises DW Healthcare Partners on Continuation Fund
December 05, 2024
Mintz advised DW Healthcare Partners (DW) on the organization of a continuation vehicle to extend DW’s investment in its portfolio company, Med Learning Group, a continuing medical education company, and to provide additional capital to support the company’s further development and growth.
Mintz advised Artemis Capital Partners, a Boston-based private equity firm focused on partnering with differentiated industrial tech companies, on its acquisition of Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency rotary joints and rotating subsystems serving mission critical ground, shipboard, submarine, aircraft, commercial, and space applications.
Mintz Advises Invited, Inc. in its Sale of Certain Assets Related to its BigShots Golf Business to Topgolf Callaway Brands Corp.
November 03, 2023
WASHINGTON, DC – Mintz served as legal counsel to Invited, Inc. in its sale of certain assets related to its BigShots Golf business to Topgolf Callaway Brands Corp.
BOSTON– Mintz represented Gradiant Corporation, a global end-to-end solutions provider of advanced water and wastewater treatment, in its Series D financing.
Deal Diary: Orrick, Paul Weiss, Mintz On Ipsen Deal For Albireo
January 9, 2023
Mintz's role acting for biotechnology company Albireo Pharma in its sale to Ipsen was covered in The Deal. The article featured Mintz Members Megan Gates, and John Condon and Associate Garrett Galvin, who led for the firm.
Mintz Takes Lead For Med-Pharmex In Its Sale To Britain’s Dechra
August 31, 2022
Mintz completed a deal as counsel to Med-Pharmex in its sale to British-owned veterinary products developer and manufacturer Dechra Pharmaceuticals. Through the sale, Dechra will gain further access and nearly 40 years of experience in the U.S. veterinary health market.
Mintz's interdisciplinary team continues its leadership role in life sciences, serving as legal counsel to ProKidney LP in its $2.6 billion SPAC merger, and its subsequent listing on the Nasdaq under the ticker symbol "PROK". ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney's lead product candidate is in Phase 3 clinical development and has the potential to slow, stabilize and reverse decline in kidney function
The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.
Recent Insights
Restrictive Covenants in Private Equity Transactions
May 14, 2025| Alert|
Mintz advised SightLine Applications, a leading developer of sensor processing software for autonomous and uncrewed systems, backed by Artemis, on its acquisition of Athena AI, an Australia-based specialist in AI-enabled computer vision and decision support for defense applications.
Mintz advised Searchlight Cyber, a portfolio company of Charlesbank Capital Partners, on the acquisition of Assetnote, an Australian-based Attack Surface Management (ASM) platform provider.
